USE OF NANOTECHNOLOGICAL CONCEPTS AND TERMINOLOGY IN MEDICINE: CURRENT APPLICATIONS, CLINICAL VALUE, AND TRANSLATIONAL CHALLENGES
DOI:
https://doi.org/10.55640/Keywords:
Nanotechnology; Nanomedicine; Nanoparticles; Liposomes; Lipid nanoparticles; Drug delivery; Medical diagnostics; Theranostics; Precision medicine; BiocompatibilityAbstract
Nanotechnology has become an important component of modern medicine because it provides new opportunities for targeted drug delivery, improved diagnostics, controlled release systems, and personalized treatment strategies. In medical literature, terms such as nanoparticles, liposomes, lipid nanoparticles, quantum dots, polymeric nanocarriers, and theranostic platforms are widely used to describe nanoscale systems designed for biomedical applications. These concepts are especially relevant in oncology, vaccine development, RNA-based therapeutics, molecular imaging, and biosensing. The present article examines the use of nanotechnological terminology in medicine and discusses its clinical significance through an IMRAD-structured review. The analysis shows that nanotechnology improves the solubility, stability, bioavailability, and targeting efficiency of therapeutic agents while also enhancing diagnostic sensitivity. At the same time, the review highlights important translational challenges, including biocompatibility, protein corona formation, manufacturing reproducibility, and regulatory standardization, which influence the safe and effective implementation of nanomedicine in clinical practice. Overall, nanotechnological terminology in medicine reflects not only a scientific vocabulary but also an evolving clinical paradigm that connects material science with patient-centered healthcare. The future of nanomedicine depends on the successful integration of innovative nanosystems into clinically practical, safe, and evidence-based medical solutions.
Downloads
References
1.Shi J, Kantoff PW, Wooster R, Farokhzad OC. Cancer nanomedicine: progress, challenges and opportunities. Nature Reviews Cancer. 2017;17(1):20-37.
2.Joyce P, Allen C, Alonso MJ, Ashford M, Bradbury M, Germain M, et al. A translational framework to DELIVER nanomedicines to the clinic. Nature Nanotechnology. 2024. doi:10.1038/s41565-024-01754-7.
3.U.S. Food and Drug Administration. New Class of Drugs Fulfills Promise of RNA-based Medicine. FDA. 2024.
4.Barenholz Y. Doxil® — The first FDA-approved nano-drug: Lessons learned. Journal of Controlled Release. 2012;160(2):117-134.
5.Cheng Y, Morshed RA, Cheng SH, Tobias A, Auffinger B, Wainwright DA, et al. Clinical translation of nanomedicines: Challenges, opportunities, and strategies. Trends in Pharmacological Sciences. 2022;43(9).
6.Mahmoudi M, Landry MP, Moore A, Coreas R. The protein corona from nanomedicine to environmental science. Nature Reviews Materials. 2023;8:422-438.
7.The untapped potential of mRNA–lipid nanoparticles. Nature Reviews Bioengineering. 2025;3:715.
8.Design principles of lipid nanoparticles for RNA delivery. Nature Reviews Bioengineering. 2026. doi:10.1038/s44222-026-00401-1.
9.Biomedical application of carbon quantum dots: A review. Materials Today Bio. 2024.
10.U.S. Food and Drug Administration. Quality Considerations and Controls for Drug Products Containing Nanomaterials. FDA. 2023.
Downloads
Published
Issue
Section
License

This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors retain the copyright of their manuscripts, and all Open Access articles are disseminated under the terms of the Creative Commons Attribution License 4.0 (CC-BY), which licenses unrestricted use, distribution, and reproduction in any medium, provided that the original work is appropriately cited. The use of general descriptive names, trade names, trademarks, and so forth in this publication, even if not specifically identified, does not imply that these names are not protected by the relevant laws and regulations.

Germany
United States of America
Italy
United Kingdom
France
Canada
Uzbekistan
Japan
Republic of Korea
Australia
Spain
Switzerland
Sweden
Netherlands
China
India